Table 1.
Baseline characteristics of the patients treated with hypofractionated or conventional radiotherapy
| Hypofractionated | Conventional | p-value | |
|---|---|---|---|
|
| |||
| Number of patients | 84 | 84 | 1.0000 |
|
| |||
| Age [years] | |||
|
| |||
| Median (range) | 66 (49–74) | 64 (48–72) | 0.7734 |
|
| |||
| T stage | |||
|
| |||
| T1a | 03 (3.7%) | 03 (3.7%) | 0.8521 |
| T1b | 08 (9.5%) | 09 (10.7%) | |
| T1c | 05 (5.6%) | 06 (7.2%) | |
| T2a | 19 (22.7%) | 20 (23.9%) | |
| T2b | 21 (25.0%) | 22 (26.2%) | |
| T2c | 17 (20.2%) | 13 (15.5%) | |
| T3a | 08 (9.6%) | 09 (10.7%) | |
| T3b | 03 (3.7%) | 02 (2.4%) | |
|
| |||
| PSA concentration [ng/mL] | |||
|
| |||
| < 10 | 28 (33.3%) | 27 (32.1%) | 0.8632 |
| 10–20 | 37 (44.0%) | 36 (42.9%) | |
| > 20 | 19 (22.7%) | 21 (25.0%) | |
|
| |||
| Gleason score | |||
|
| |||
| ≤ 6 | 29 (34.5%) | 28 (33.3%) | 0.8743 |
| 7 | 36 (42.9%) | 35 (41.7%) | |
| 8–10 | 19 (22.7%) | 21 (25.0%) | |
|
| |||
| Risk group | |||
|
| |||
| Intermediate | 51 (60.7%) | 50 (61.9%) | 0.8645 |
| High | 33 (39.3%) | 34 (38.1%) | |
|
| |||
| Comorbidities (HTN/DM) | 36 (42.9%) | 34 (40.5%) | 0.7743 |
|
| |||
| Prostate volume [cm 3 ] | |||
|
| |||
| ≤ 50 | 38 (45.2%) | 40 (47.6%) | 0.7665 |
| > 50 | 46 (54.8%) | 44 (52.4%) | |
PSA — prostate specific antigen; HTN — hypertension; DM — diabetes mellitus